logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11446315 B1

PDFFull Text
Date of Patent:
Sep. 20, 2022

Filed:

Nov. 01, 2017

Enhancement of cd47 blockade therapy by proteasome inhibitors

Applicant:

Pf Argentum Ip Holdings Llc, New york, NY (US);

Inventors:

Emma Linderoth, Toronto, CA;

Natasja Nielsen Viller, Oakville, CA;

Robert Adam Uger, Richmond Hill, CA;

Penka Slavcheva Slavova-Petrova, Toronto, CA;

Assignee:

PF Argentum IP Holdings LLC, New York, NY (US);

Attorney:

Stephen E. Moyer

Primary Examiner:

Jeffrey E Russel

Int. Cl.
CPC ...
A61K 38/08 (2019.01); A61K 38/17 (2006.01); A61K 47/68 (2017.01); A61K 31/69 (2006.01); A61P 35/02 (2006.01); A61K 31/5355 (2006.01); A61K 38/07 (2006.01); C07K 7/06 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07F 5/02 (2006.01); C07F 5/04 (2006.01); C07K 16/00 (2006.01); A61K 38/00 (2006.01); A61K 38/05 (2006.01);
U.S. Cl.
CPC ...
A61K 31/69 (2013.01); A61K 31/5355 (2013.01); A61K 38/005 (2013.01); A61K 38/07 (2013.01); A61K 38/08 (2013.01); A61K 38/17 (2013.01); A61K 38/177 (2013.01); A61K 47/68 (2017.08); A61K 47/6811 (2017.08); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07F 5/025 (2013.01); C07F 5/04 (2013.01); C07K 7/06 (2013.01); C07K 14/705 (2013.01); C07K 14/70596 (2013.01); C07K 16/00 (2013.01); C07K 16/2803 (2013.01); A61K 38/00 (2013.01); A61K 38/05 (2013.01); C07K 2319/30 (2013.01);
Abstract

CD47− disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of bortezomib, ixazomib and carfilzomib as proteasome inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.

Find Patent Forward Citations

Linderoth, Emma. (2022). Enhancement of cd47 blockade therapy by proteasome inhibitors (U.S. Patent No. 11446315). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11446315

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…